GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » EV-to-EBITDA

Quest PharmaTech (TSXV:QPT) EV-to-EBITDA : -0.19 (As of May. 05, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Quest PharmaTech's enterprise value is C$4.29 Mil. Quest PharmaTech's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was C$-22.24 Mil. Therefore, Quest PharmaTech's EV-to-EBITDA for today is -0.19.

The historical rank and industry rank for Quest PharmaTech's EV-to-EBITDA or its related term are showing as below:

TSXV:QPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.12   Med: -8.68   Max: 37.13
Current: -0.19

During the past 13 years, the highest EV-to-EBITDA of Quest PharmaTech was 37.13. The lowest was -57.12. And the median was -8.68.

TSXV:QPT's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.55 vs TSXV:QPT: -0.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Quest PharmaTech's stock price is C$0.02. Quest PharmaTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-0.123. Therefore, Quest PharmaTech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Quest PharmaTech EV-to-EBITDA Historical Data

The historical data trend for Quest PharmaTech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech EV-to-EBITDA Chart

Quest PharmaTech Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.39 -1.40 0.17 -0.18 -1.71

Quest PharmaTech Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -1.71 -1.17 -0.66 -0.54

Competitive Comparison of Quest PharmaTech's EV-to-EBITDA

For the Biotechnology subindustry, Quest PharmaTech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest PharmaTech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's EV-to-EBITDA falls into.



Quest PharmaTech EV-to-EBITDA Calculation

Quest PharmaTech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4.289/-22.235
=-0.19

Quest PharmaTech's current Enterprise Value is C$4.29 Mil.
Quest PharmaTech's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-22.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quest PharmaTech  (TSXV:QPT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Quest PharmaTech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.02/-0.123
=At Loss

Quest PharmaTech's share price for today is C$0.02.
Quest PharmaTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.123.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Quest PharmaTech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest PharmaTech (TSXV:QPT) Business Description

Traded in Other Exchanges
N/A
Address
8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines